Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2020, Vol. 52 ›› Issue (3): 570-577. doi: 10.19723/j.issn.1671-167X.2020.03.026

Previous Articles     Next Articles

Characteristic and clinical significance of microRNA expression between 144 Uygur and Han women with endometrial carcinoma

Xiao WANG1,Dan HE1,Wen-ting LI2,SIYITI Adila·2,Rui HAN1,Ying DONG1,△()   

  1. 1. Department of Pathology, Peking University First Hospital, Beijing 100034, China
    2. Department of Pathology, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi 830011, China
  • Received:2018-04-02 Online:2020-06-18 Published:2020-06-30
  • Contact: Ying DONG E-mail:dongying_999@163.com
  • Supported by:
    National Natural Science Foundation of China(81360381)

RICH HTML

 1   

PDF (PC)

141

Abstract:

Objective: To compare the expression patterns of microRNA (miRNA) between 144 Uygur and Han women with endometrial carcinoma and to investigate their clinical significance.Methods: Taqman miRNA low-density array was used to compare miRNA profiles between Uygur and Han women with non-endometrioid endometrial carcinoma (NEEC). Five miRNAs were further analyzed in the 144 endometrial cancers including 62 Uygur and 82 Han samples via real-time PCR to determine their expression patterns.Results: MiRNA expression profiles revealed that many miRNAs overexpressed or downregula-ted in one ethnic group, but did not express or changed slightly in the other ethnic group. Further detection in the 144 endometrial cancers showed that miR-141, miR-200a, and miR-205 overexpressed in both ethnic groups. In Uygur endometrioid endometrial carcinoma (EEC), tumors with miR-141/200a overexpression tended to be more aggressive in behavior, whereas in the Han group, EEC with miR-200a overexpression was relative mild. However, the NEEC with miR-200a overexpression also had aggressive clinicopathologic features in the Han women. MiR-145 and miR-143 expressed differentially between Uygur and Han groups, they overexpressed in the former and decreased in the latter (P<0.05). In the Uygur women miR-145/143 increased significantly in NEEC and there was a trend that NEEC exhibiting favorable clinicopathologic factors had higher miR-145 expression, and was statistically significant in tumors with myometrial invasion less than 1/2 thickness (P=0.042). By contrary, miR-145/143 decreased in Han group and EEC with worse clinicopathologic variables had lower expression although without statistical significance. NEEC in Han group had no such tendency.Conclusion: Uygur and Han women might have different miRNA expression profiles. MiR-141/200a/205 overexpressed in endometrial carcinomas and miR-141/200a might behave differently between these two ethnic groups as well as in EEC and in NEEC. Although miR-145/143 showed inverse expression patterns between Uygur and Han women with endometrial cancer, they all exerted tumor suppression effect on endometrial cancer.

Key words: Endometrial carcinoma, Carcinoma, endometrioid, MicroRNAs

CLC Number: 

  • R737.33

Table 1

Differentially expressed miRNAs in Uygur and Han women with non-endometrioid endometrial carcinoma"

miRNA log2 (relative quantity)
Uygur Han
hsa-miR-101#-002143 0.071 15.513
hsa-miR-876-3p-4395336 0.053 10.105
hsa-miR-299-5p-4373188 0.037 87.624
hsa-miR-885-5p-4395407 0.019 47.159
hsa-miR-218-2#-002294 0.012 32.331
hsa-let-7c#-002405 0.012 526.021
hsa-miR-450b-5p-4395318 0.003 334.49
hsa-miR-876-5p-4395316 0.003 334.728
hsa-miR-643-001594 0.003 516.767
hsa-miR-497#-002368 0.001 265.121
hsa-miR-29b-1#-002165 0.001 295.243
hsa-miR-504-4395195 0 363.642
hsa-miR-296-3p-4395212 0 2 683.919
hsa-miR-941-002183 0 4 023.437
hsa-miR-1267-002885 94 877.297 0
hsa-miR-486-3p-4395204 14 529.595 0
hsa-miR-654-5p-4381014 3 411.37 0.001
hsa-miR-541-4395312 3 315.935 0
hsa-miR-431-4395173 3 306.269 0.001
hsa-miR-486-5p-4378096 1 747.636 0.075
hsa-miR-452#-002330 169.787 0.004
hsa-miR-548J-002783 85.613 0.004
hsa-miR-523-4395497 19.512 0.049

Figure 1

Relative expression of miR-141, miR-200a, miR-205, miR-143, and miR-145 in the Uygur and Han women with endometrial cancer"

Table 2

Expression of miR-141, miR-200a, miR-205, miR-143, and miR-145 in the Uygur women with EEC (n=49) or NEEC (n=13)"

Variable log2 (relative quantity),mean±SE
miR-141 miR-200a miR-205 miR-143 miR-145
EEC NEEC EEC NEEC EEC NEEC EEC NEEC EEC NEEC
Histologic type 4.60±0.42 3.65±0.79 5.12±0.42 4.45±0.69 4.44±0.40 4.02±0.69 0.52±0.51 2.04±0.73 1.99±0.56 3.95±0.83
P <0.001 0.003 <0.001 <0.001 <0.001 0.001 0.504 0.040 0.013 <0.001
Age
Premenopause (n=25) 4.69±0.68 3.65±0.24 4.93±0.72 2.44±1.71 4.27±0.75 4.21±0.64 0.52±0.68 1.92±2.04 2.25±0.98 3.54±0.95
Postmenopause (n=37) 4.53±0.55 3.65±1.04 5.28±0.50 5.05±0.68 4.58±0.61 3.97±0.90 0.53±0.75 2.07±0.81 1.79±0.65 4.07±1.06
P 0.854 0.999 0.687 0.115 0.751 0.894 0.991 0.935 0.688 0.801
Grade (EEC)
Low (n=21) 4.33±0.68 - 4.87±0.45 - 4.49±0.78 - 1.08±0.93 - 2.20±0.62 -
High (n=28) 4.81±0.55 - 6.93±0.76 - 4.41±0.59 - 0.10±0.55 - 0.52±1.06 -
P 0.580 0.044 0.934 0.371 0.376
Myometrial invasiona
<1/2 (n=35) 4.17±0.55 1.28±1.77 4.76±0.56 1.53±0.88 3.81±0.61 1.85±1.62 -0.39±0.57 3.90±1.20 1.40±0.76 5.98±1.13
≥1/2 (n=13) 5.72±0.81 4.48±0.66 6.14±0.81 5.53±0.47 4.83±1.73 4.84±0.52 -0.88±0.75 1.11±0.90 0.65±0.99 2.86±1.08
P 0.284 0.167 0.225 0.011 0.547 0.160 0.617 0.099 0.945 0.042
Lymph node metastasesb
No (n=37) 4.35±0.62 4.04±0.71 5.03±0.60 4.53±0.79 3.88±0.74 4.28±0.68 -0.36±0.63 2.46±0.90 1.61±0.87 4.08±1.07
Yes (n=4) 5.40±1.07 3.44 5.69±1.09 3.26 3.98±1.82 4.63 -0.80±0.47 -0.56 0.51±0.74 1.86
P 0.590 0.807 0.704 0.343 0.964 0.879 0.588 0.337 0.809 0.527
Vessel invasiona
No (n=38) 4.36±0.54 3.00±1.17 4.86±0.54 3.66±1.04 3.96±0.62 3.65±0.85 -0.58±0.54 2.11±1.27 1.24±0.75 3.92±1.05
Yes (n=10) 4.55±1.40 3.97±1.21 5.53±1.26 4.94±0.85 3.90±1.61 4.11±1.41 0.30±1.30 1.95±0.90 1.62±1.23 3.88±1.73
P 0.900 0.586 0.909 0.465 0.970 0.771 0.547 0.924 0.450 0.935
Stagea
Ⅰ or Ⅱ (n=40) 4.30±0.53 3.81±1.21 4.89±0.53 4.21±1.12 3.95±0.61 3.47±0.85 -0.43±0.54 1.47±1.03 1.37±0.72 4.57±2.06
Ⅲ or Ⅳ (n=8) 5.40±1.07 2.85±1.11 5.69±1.09 4.16±0.76 3.98±1.82 4.37±1.37 -0.80±0.47 2.84±1.30 0.51±0.74 3.43±0.66
P 0.546 0.588 0.358 0.194 0.989 0.570 0.617 0.422 0.932 0.570

Table 3

Expression of miR-141, miR-200a, miR-205, miR-143, and miR-145 in the Han women with EEC (n=53) or NEEC (n=29)"

Variable log2 (relative quantity), mean±SE
miR-141 miR-200a miR-205 miR-143 miR-145
EEC NEEC EEC NEEC EEC NEEC EEC NEEC EEC NEEC
Histologic type 2.63±0.34 4.82±1.01 2.61±0.38 5.81±1.30 4.51±0.52 4.31±0.79 -2.43±0.34 -0.13±1.16 -2.61±0.32 -2.70±0.92
P 0.023 <0.001 <0.001 <0.001 0.012 0.015 <0.001 0.009 0.001 0.187
Age
Premenopause (n=28) 2.78±0.56 4.79±1.84 1.76±0.70 8.21±1.64 4.97±0.84 5.18±1.55 -2.22±0.53 -2.54±1.34 -1.94±0.53 0.84±2.81
Postmenopause (n=54) 2.55±0.43 4.62±0.98 3.12±0.42 5.03±1.31 4.23±0.67 4.35±0.71 -2.85±0.39 -1.73±0.69 -2.73±0.44 0.01±0.83
P 0.751 0.934 0.082 0.247 0.499 0.606 0.334 0.596 0.267 0.702
Grade (EEC)
Low (n=28) 2.60±0.46 - 2.64±0.42 - 3.89±0.80 - -2.39±0.46 - -2.36±0.37 -
High (n=25) 2.68±0.51 - 2.43±0.86 - 5.20±0.64 - -2.86±0.43 - -2.92±0.80 -
P 0.907 0.694 0.212 0.470 0.446
Myometrial invasiona
<1/2 (n=62) 2.55±0.43 4.62±0.98 2.63±0.41 5.43±1.49 4.67±0.54 4.40±0.71 -2.32±0.35 -2.43±0.82 -2.26±0.36 -0.73±1.33
≥1/2 (n=19) 2.88±0.46 4.31±1.95 2.55±0.81 7.08±3.16 4.06±1.30 3.95±1.56 -3.41±0.66 -1.70±0.85 -2.90±0.83 1.91±2.22
P 0.603 0.876 0.817 0.614 0.609 0.762 0.129 0.609 0.431 0.160
Lymph node metastasesb
No (n=32) 2.72±0.58 5.05±1.20 3.19±0.63 5.70±2.05 4.35±1.12 4.53±0.85 -2.15±0.58 -1.92±0.89 -1.84±0.69 -0.02±1.57
Yes (n=8) 2.29±1.32 5.21±0.90 2.71±1.69 6.36±1.35 4.02±1.13 2.00±1.65 -2.82±0.79 -4.97±1.90 -2.51±1.05 -3.23±1.71
P 0.738 0.956 0.411 0.671 0.879 0.229 0.567 0.172 0.457 0.457
Vessel invasiona
No (n=67) 2.69±0.38 4.47±1.03 2.77±0.38 5.68±1.57 4.48±0.61 4.39±0.78 -2.45±0.36 -2.54±0.76 -2.35±0.37 -0.35±1.44
Yes (n=14) 2.37±0.78 4.78±1.70 1.84±1.25 6.42±2.81 4.65±0.70 3.80±1.19 -3.40±0.62 -0.96±0.67 -2.81±0.88 0.93±0.90
P 0.733 0.891 0.255 0.867 0.906 0.727 0.260 0.322 0.602 0.073
Stagea
Ⅰ or Ⅱ (n=68) 2.63±0.37 3.81±0.99 2.71±0.38 4.53±1.60 4.49±0.59 4.21±0.66 -2.45±0.34 -1.83±0.70 -2.27±0.36 -0.42±1.28
Ⅲ or Ⅳ (n=13) 2.67±0.94 6.97±1.73 1.98±1.53 9.77±1.91 4.64±0.87 4.49±1.96 -3.64±0.77 -3.56±1.38 -3.51±0.97 0.98±2.63
P 0.970 0.134 0.587 0.570 0.925 0.862 0.204 0.252 0.172 0.507

Figure 2

Overexpression rate of DNMT3B in the Uygur and Han women DNMT3B, DNA methyltransferase 3B; EC, endometrial carcinoma; EEC, endometrioid endometrial carcinoma; NEEC, non-endometrioid endometrial carcinoma."

Table 4

DNMT3B expression in the Uygur and Han women with endometrial cancer"

Variable DNMT3B overexpression
Uygur Han
EEC NEEC EEC NEEC
Histologic type 67.3% (33/49) 84.6% (11/13) 60.4% (32/53) 41.4% (12/29)
P 0.312 0.099
Grade (EEC)
Low 65.1% (28/43) - 58.7% (27/46) -
High 83.3%(5/6) - 71.4% (5/7) -
P 0.690 0.649
Myometrial invasion
<1/2 64.5% (20/31) 50.0% (2/4) 61.5% (24/39) 33.3% (7/21)
≥1/2 100.0% (5/5) 100.0% (8/8) 57.1% (4/7) 57.1% (4/7)
P 0.295 0.091 0.773 0.381
Lymph node metastases
No 66.7% (18/27) 90.0% (9/10) 47.1% (8/17) 57.1% (8/14)
Yes 50.0% (1/2) 100.0% (1/1) 80.0% (4/5) 50.0% (2/4)
P 0.323 >0.999 0.534 >0.999
Vessel invasion
No 66.7% (21/31) 71.4% (5/7) 59.1% (26/44) 40.9% (9/22)
Yes 80.0% (4/5) 100.0% (5/5) 66.7% (6/9) 33.3% (2/6)
P 1.000 0.470 >0.999 >0.999
Stage
Ⅰ or Ⅱ 66.7% (22/33) 71.4% (5/7) 58.1% (27/46) 38.1% (8/21)
Ⅲ or Ⅳ 100.0% (3/3) 100.0% (5/5) 71.4% (5/7) 42.9% (3/7)
P 0.538 0.470 0.690 >0.999
[1] 廖秦平, 杨曦. 子宫内膜癌筛查及早期诊断的现状及展望. 实用妇产科杂志, 2015,31(7):481-484.
[2] Cancer Genome Atlas Research, Network. Integrated genomic characterization of endometrial carcinoma[J]. Nature, 2013,497(7447):67-73.
[3] Schimp VL, Ali-Fehmi R, Solomon LA, et al. The racial disparity in outcomes in endometrial cancer: could this be explained on a molecular level?[J]. Gynecol Oncol, 2006,102(3):440-446.
[4] Srivastava SK, Ahmad A, Zubair H, et al. MicroRNAs in gynecological cancers: Small molecules with big implications[J]. Cancer Lett, 2017,407:123-138.
[5] Robert JK, Maria LC, Herrington CS, et al. WHO classification of tumours of female reproductive organs[M]. Lyon, France: World Health Organization, 2014: 121-154.
[6] 董颖, 周梅, 巴晓军, 等. 子宫内膜癌中DNA甲基转移酶3B的表达特点与临床意义[J]. 北京大学学报(医学版), 2016,48(5):788-794.
[7] Chen T, Ding L, Shan G, et al. Prevalence and racial differences in pterygium: a cross-sectional study in Han and Uygur adults in Xinjiang, China[J]. Invest Ophthalmol Vis Sci, 2015,56(2):1109-1117.
[8] Lee JW, Park YA, Choi JJ, et al. The expression of the miRNA-200 family in endometrial endometrioid carcinoma[J]. Gynecol Oncol, 2011,120(1):56-62.
[9] Ratner ES, Tuck D, Richter C, et al. MicroRNA signatures differentiate uterine cancer tumor subtypes[J]. Gynecol Oncol, 2010,118(3):251-257.
[10] Chung TK, Cheung TH, Huen NY, et al. Dysregulated micro-RNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women[J]. Int J Can-cer, 2009,124(6):1358-1365.
[11] 刘霞, 夏伟, 代荫梅, 等. 子宫内膜腺癌组织中miRNA的差异表达[J]. 中华医学杂志, 2009,89(19):1365-1367.
[12] Wu W, Lin Z, Zhuang Z, et al. Expression profile of mammalian microRNAs in endometrioid adenocarcinoma[J]. Eur J Cancer Prev, 2009,18(1):50-55.
[13] Hiroki E, Akahira J, Suzuki F, et al. Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas[J]. Cancer Sci, 2010,101(1):241-249.
[14] Devor EJ, Hovey AM, Goodheart MJ, et al. microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs[J]. Oncol Rep, 2011,26(4):995-1002.
pmid: 21725615
[15] Snowdon J, Zhang X, Childs T, et al. The microRNA-200 family is upregulated in endometrial carcinoma[J]. PLoS One, 2011,6(8):e22828.
doi: 10.1371/journal.pone.0022828 pmid: 21897839
[16] Torres A, Torres K, Pesci A, et al. Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endome-trioid endometrial carcinoma patients[J]. Int J Cancer, 2013,132(7):1633-1645.
doi: 10.1002/ijc.27840 pmid: 22987275
[17] Bauer KM, Hummon AB. Effects of the miR-143/-145 microRNA cluster on the colon cancer proteome and transcriptome[J]. J Proteome Res, 2012,11(9):4744-4754.
doi: 10.1021/pr300600r
[18] Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets[J]. Proc Natl Acad Sci USA, 2006,103(7):2257-2261.
doi: 10.1073/pnas.0510565103 pmid: 16461460
[19] Zhang X, Dong Y, Ti H, et al. Down-regulation of miR-145 and miR-143 might be associated with DNA methyltransferase 3B overexpression and worse prognosis in endometrioid carcinomas[J]. Hum Pathol, 2013,44(11):2571-2580.
doi: 10.1016/j.humpath.2013.07.002
[1] ZHOU Chuan-xiang,ZHOU Zheng,ZHANG Ye,LIU Xiao-xiao,GAO Yan. Clinicopathological study in 28 cases of oral basaloid squamous cell carcinomas [J]. Journal of Peking University (Health Sciences), 2022, 54(1): 62-67.
[2] SU Jun-qi,SONG Yang,XIE Shang. Analysis of etiological characteristics and establishment of prediction model of postoperative infections in patients undergoing oral squamous cell carcinoma surgery with free flap reconstruction [J]. Journal of Peking University (Health Sciences), 2022, 54(1): 68-76.
[3] Yu TIAN,Xiao-yue CHENG,Hui-ying HE,Guo-liang WANG,Lu-lin MA. Clinical and pathological features of renal cell carcinoma with urinary tract tumor thrombus: 6 cases report and literature review [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 928-932.
[4] YU Yan-fei,HE Shi-ming,WU Yu-cai,XIONG Sheng-wei,SHEN Qi,LI Yan-yan,YANG Feng,HE Qun,LI Xue-song. Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 640-646.
[5] SUN Zheng-hui,HUANG Xiao-juan,DONG Jing-han,LIU Zhuo,YAN Ye,LIU Cheng,MA Lu-lin. Risk factors of renal sinus invasion in clinical T1 renal cell carcinoma patients undergoing nephrectomy [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 659-664.
[6] XIAO Ruo-tao,LIU Cheng,XU Chu-xiao,HE Wei,MA Lu-lin. Prognostic value of preoperative platelet parameters in locally advanced renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 647-652.
[7] PANG Yong,ZHANG Sha,YANG Hua,ZHOU Rou-li. Serum LAPTM4B-35 protein as a novel diagnostic marker for hepatocellular carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 710-715.
[8] ZHAO Xun,YAN Ye,HUANG Xiao-juan,DONG Jing-han,LIU Zhuo,ZHANG Hong-xian,LIU Cheng,MA Lu-lin. Influence of deep invasive tumor thrombus on the surgical treatment and prognosis of patients with non-metastatic renal cell carcinoma complicated with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 665-670.
[9] HAN Song-chen,HUANG Zi-xiong,LIU Hui-xin,XU Tao. Renal functional compensation after unilateral radical nephrectomy of renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 680-685.
[10] HONG Peng,TIAN Xiao-jun,ZHAO Xiao-yu,YANG Fei-long,LIU Zhuo,LU Min,ZHAO Lei,MA Lu-lin. Bilateral papillary renal cell carcinoma following kidney transplantation: A case report [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 811-813.
[11] LIAO Xu-he,WANG Rong-fu,LIU Meng,CHEN Xue-qi,XIONG Yan,NONG Lin,YIN Lei,ZHANG Bing-ye,DU Yu-jing. Semiquantitative parameters of 18F-FDG PET/CT, gene mutation states of epidermal growth factor receptor and anaplastic lymphoma kinase in prognosis evaluation of patients with lung adenocarcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 246-254.
[12] WANG Ying-chun,HUANG Yong-hui,CHANG Hong,YAO Wei,YAN Xiu-e,LI Ke,ZHANG Yao-peng,ZHENG Wei. Characteristics of benign and malignant lesions of ampullary polyps and the accuracy of forceps biopsy [J]. Journal of Peking University (Health Sciences), 2021, 53(1): 204-209.
[13] Lei-zhen SU,Jie CHEN,Xian LI,Ping JI. Effects of salinomycin on proliferation and apoptosis of oral squamous cell carcinoma [J]. Journal of Peking University (Health Sciences), 2020, 52(5): 902-906.
[14] Bo MA,Zhi-hua TIAN,Li QU,Yue-xiang LIU,Hong ZHANG,Hui-rong DING. Establishment and gene expression analysis of drug-resistant cell lines in hepatocellular carcinoma induced by sorafenib [J]. Journal of Peking University (Health Sciences), 2020, 52(2): 207-213.
[15] Ye ZHANG,Ni ZHANG,Xiao-xiao LIU,Chuan-xiang ZHOU. Cervical lymph node metastasis in adenoid cystic carcinoma of the salivary glands: A clinicopathologic study [J]. Journal of Peking University(Health Sciences), 2020, 52(1): 30-34.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] Author. English Title Test[J]. Journal of Peking University(Health Sciences), 2010, 42(1): 1 -10 .
[2] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 188 -191 .
[3] . [J]. Journal of Peking University(Health Sciences), 2009, 41(3): 376 -379 .
[4] . [J]. Journal of Peking University(Health Sciences), 2009, 41(4): 459 -462 .
[5] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 319 -322 .
[6] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 333 -336 .
[7] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 337 -340 .
[8] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 225 -328 .
[9] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 346 -350 .
[10] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 369 -373 .
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd